The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
zuo zuo bu fen (indobufen) yu fang xin zang bing bing ren de xue shuan bing fa zheng
Author(s): 
Pages: 372
Year: Issue:  6
Journal: World Clinical Drugs

Keyword:  心脏病病人Indobufen吲哚布芬体循环栓塞一过性脑缺血慢性房颤窦性心律肺栓塞安慰剂对照环氧化酶抑制剂;
Abstract: <正> 吲哚布芬(indobufen)是一种可逆性血小板环氧化酶抑制剂。本文采用随机、双盲、安慰剂对照试验评价了本品预防心源性血栓并发症的效果。 196例心脏病病人参加了本研究,均有发生心源性血栓的危险因素,其中90例病人为慢性房颤,106例为窦性心律。所有病人在过去的6个月内未服过抗凝药或抗血小板聚集剂,让病人随机接受本品100mg每日2次(98例)或安慰剂(98例),以后每3个月复查一次,共随访3年,主要研究终点为脑缺血发作(中风和一过性脑缺血发作),体循环栓塞、肺栓塞和致命性心肌梗塞。
Related Articles
No related articles found